ADMA Biologics Inc (ADMA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ADMA Biologics Inc (ADMA) has a cash flow conversion efficiency ratio of 0.149x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($58.25 Million) by net assets ($390.32 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ADMA Biologics Inc (ADMA) liquidity interval to measure how many days the company can operate on defensive assets alone.
ADMA Biologics Inc - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how ADMA Biologics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
ADMA Biologics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ADMA Biologics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Newell Rubbermaid Inc.
NASDAQ:NWL
|
0.067x |
|
Jiangsu New Energy Development Co Ltd
SHG:603693
|
0.063x |
|
Charter Hall Long Wale REIT
AU:CLW
|
0.027x |
|
Citic Offshore Helicopter Co Ltd
SHE:000099
|
0.009x |
|
TPV Technology Co Ltd
SHE:000727
|
-0.186x |
|
Sichuan Anning Iron and Titanium Co
SHE:002978
|
-0.070x |
|
Shanghai Bailian Group Co Ltd A
SHG:600827
|
0.011x |
|
Nanjing Gaoke Co Ltd
SHG:600064
|
0.010x |
Annual Cash Flow Conversion Efficiency for ADMA Biologics Inc (2006–2025)
The table below shows the annual cash flow conversion efficiency of ADMA Biologics Inc from 2006 to 2025. For the full company profile with market capitalisation and key ratios, see market value of ADMA Biologics Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $477.32 Million | $50.40 Million | 0.106x | -68.95% |
| 2024-12-31 | $349.02 Million | $118.67 Million | 0.340x | +422.41% |
| 2023-12-31 | $135.21 Million | $8.80 Million | 0.065x | +116.62% |
| 2022-12-31 | $151.97 Million | $-59.51 Million | -0.392x | +50.81% |
| 2021-12-31 | $141.17 Million | $-112.37 Million | -0.796x | +31.14% |
| 2020-12-31 | $88.25 Million | $-102.00 Million | -1.156x | +60.27% |
| 2019-12-31 | $26.19 Million | $-76.19 Million | -2.909x | +8.25% |
| 2018-12-31 | $19.77 Million | $-62.68 Million | -3.170x | -243.07% |
| 2017-12-31 | $40.33 Million | $-37.27 Million | -0.924x | -122.55% |
| 2016-12-31 | $-4.46 Million | $-18.27 Million | 4.099x | +121.82% |
| 2015-12-31 | $820.97K | $-15.42 Million | -18.781x | -667.40% |
| 2014-12-31 | $6.01 Million | $-14.70 Million | -2.447x | -384.94% |
| 2013-12-31 | $21.57 Million | $-10.89 Million | -0.505x | +31.11% |
| 2012-12-31 | $9.42 Million | $-6.90 Million | -0.733x | +92.99% |
| 2011-12-31 | $2.77K | $-29.00K | -10.458x | -118.39% |
| 2010-12-31 | $-346.00 | $-19.68K | 56.867x | -- |
| 2009-12-31 | $0.00 | $-24.46 Million | x | -- |
| 2008-12-31 | $0.00 | $-19.00 Million | x | -- |
| 2007-12-31 | $0.00 | $-23.61 Million | x | -- |
| 2006-12-31 | $0.00 | $-23.61 Million | x | -- |
About ADMA Biologics Inc
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indic… Read more